Health · 4 views
ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant benefits for adults aged 80 years and older with chronic kidney disease (CKD), according to a study presented at Kidney Week, the annual meeting of the American Society of…
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant benefits for adults aged 80 years and older with chronic kidney disease (CKD), according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 21 to 25 in Denver. Julian Doricic, M.D., from Medizinische Hochschule Hannover in Germany, and colleagues examined effects of SGLT2 inhibitor therapy in elderly adults with CKD.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- The invisible global health workforce: Why nurses matter more than everContinue reading
- AI measurements of heart scans more strongly linked to patient survival than clinician measurementsContinue reading
- Novel Therapy Lands Speedy Approval for Wart-Like Airway DiseaseContinue reading
- Study Strengthens Case for Stent-Free PCI in De Novo Coronary LesionsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow